Search results for " recombinant" in Articles / App Notes
Article
Concentrating Feed—an Applicable Approach to Improve Antibody Production
These straightforward approaches can be applied to large-scale production of recombinant proteins.
Materials and methods
Cell lines. Three recombinant Chinese hamster ovary (CHO) cell li…
Article
Addressing the Challenges in Downstream Processing Today and Tomorrow
Most companies had few recombinant products licensed or in development, including insulin, somatotropin, interferon, tissue plasminogen activator, erythropoietin, Factor VIII, and Factor IX. There wer…
Article
Process development using a nonaffinity method vs Cytiva™ Protein Select™ resin
In this study, we compared two approaches for purifying a recombinant protein that does not have an affinity binding partner.
The first method is using nonaffinity chromatography steps (AI…
Article
Recap: Chromatography + filtration virtual summit 2024
Don’t worry – here are the highlights and session recordings from the event on optimizing purification and filtration for mAbs, antibody variants, recombinant proteins, and gene therapy.
See highli…
Article
Detailed agenda for Chromatography + filtration virtual summit
Join Cytiva Chromatography and filtration summit online to learn from presentations, live Q&A, and panel discussions on recent advances in antibody, antibody variants, recombinant proteins, and gene t…
Article
Enhancing Resins Addresses Purification Concerns
Although recombinant vaccines are manufactured using well-established technology, proven to be both safe and effective, they take longer to develop. DNA or mRNA vaccines, however, use information from…
Article
The Outlook for CMO Outsourcing in 2019
Rather than just familiar-type recombinant proteins and monoclonal antibodies, CMOs are often the pioneers in terms of manufacturing novel products, including antibodies with novel core structures/bac…
Article
State of the Biopharmaceutical Industry: Lessons from 2018 Survey Data
Survey data show that the lowest costs currently being attained with commercial scale recombinant protein/antibody manufacturing are now in the $100/gram range, with a few of the very largest faciliti…
Article
Modern Manufacturing Key to More Effective Vaccines
In 2017, FDA’s Center for Biologics Evaluation and Research (CBER) approved GlaxoSmithKline’s new Shingrix vaccine against shingles and a new recombinant hepatitis B preventive from Dynavax Technologi…
Article
Platform Technologies Improve Protein Expression
“In the rapidly growing market of recombinant proteins and antibodies, our STEP technology provides a tool to complete preclinical phases at higher speed with reduced costs and with a higher success r…